Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy

Although medical cancer treatment has improved during the past decades, it is difficult to choose between several first-line treatments supposed to be equally active in the diagnostic group. It is even more difficult to select a treatment after the standard protocols have failed. Any guidance for selection of the most effective treatment is valuable at these critical stages. We describe the principles and procedures for ex vivo assessment of drug activity in tumor cells from patients as a basis for tailored cancer treatment. Patient tumor cells are assayed for cytotoxicity with a panel of drugs. Acoustic drug dispensing provides great flexibility in the selection of drugs for testing; currently, up to 80 compounds and/or combinations thereof may be tested for each patient. Drug response predictions are obtained by classification using an empirical model based on historical responses for the diagnosis. The laboratory workflow is supported by an integrated system that enables rapid analysis and automatic generation of the clinical referral response.

[1]  J. Bergh,et al.  Detection of tumor‐specific cytotoxic drug activity IN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients , 1994, International journal of cancer.

[2]  R. Larsson,et al.  Predictive tests for individualization of pharmacological cancer treatment. , 2008, Expert opinion on medical diagnostics.

[3]  Lippman Me,et al.  Clonogenic and nonclonogenic in vitro chemosensitivity assays , 1985 .

[4]  R. Larsson,et al.  Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). , 1994, Gynecologic oncology.

[5]  Ola Spjuth,et al.  Brunn: An open source laboratory information system for microplates with a graphical plate layout design process , 2011, BMC Bioinformatics.

[6]  J. Sierra,et al.  Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. , 2014, Clinical lymphoma, myeloma & leukemia.

[7]  A. G. Bosanquet Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay , 1991, The Lancet.

[8]  Krister Wennerberg,et al.  Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.

[9]  Peter Nygren,et al.  Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA) , 1992, International journal of cancer.

[10]  R. Larsson,et al.  In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA) , 1997, International journal of cancer.

[11]  J. Bergh,et al.  Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Larsson,et al.  Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemia. , 1993, European journal of cancer.

[13]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[14]  L. Weisenthal,et al.  Clonogenic and nonclonogenic in vitro chemosensitivity assays. , 1985, Cancer treatment reports.

[15]  R. Larsson,et al.  In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA). , 1993, British Journal of Cancer.